Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

ClinicalTrials.gov ID: NCT04746911

Public ClinicalTrials.gov record NCT04746911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 2 to 5 Years Old) With Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:

Study identification

NCT ID
NCT04746911
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Enrollment
10 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
2 Years to 5 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2021
Primary completion
May 10, 2022
Completion
May 10, 2022
Last update posted
Aug 6, 2026

2021 – 2022

United States locations

U.S. sites
16
U.S. states
6
U.S. cities
13
Facility City State ZIP Site status
Arcutis Clinical Site 603 Mountain Brook Alabama 35223
Arcutis Clinical Site 604 Scottsdale Arizona 85255
Arcutis Clinical Site 609 Fountain Valley California 92708
Arcutis Clinical Site 618 Los Angeles California 90017
Arcutis Clinical Site 608 Los Angeles California 90057
Arcutis Clinical Site 611 Rancho Santa Margarita California 92688
Arcutis Clinical Site 610 Boca Raton Florida 33428
Arcutis Clinical Site 602 Coral Gables Florida 33146
Arcutis Clinical Site 613 Delray Beach Florida 33484
Arcutis Clinical Study Site 628 Miami Florida 33125
Arcutis Clinical Site 607 Miami Florida 33155
Arcutis Clinical Site 627 West Lafayette Indiana 47906
Arcutis Clinical Site 606 Arlington Texas 76001
Arcutis Clinical Site 619 Frisco Texas 75034
Arcutis Clinical Study Site 619 Frisco Texas 75034
Arcutis Clinical Site 605 Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04746911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04746911 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →